Terns Pharmaceuticals Stock Price, News & Analysis

Terns Pharmaceuticals, Inc. (Nasdaq: TERN) is a clinical-stage oncology company that focuses on developing medicines based on known biology. The company describes its approach as "reimagining known biology to deliver high impact medicines," with an emphasis on cancer indications. Terns is listed on the Nasdaq Global Select Market under the trading symbol TERN and is associated in SEC filings with Foster City, California.

The centerpiece of Terns Pharmaceuticals’ pipeline is TERN-701, which the company repeatedly identifies as its lead program. TERN-701 is described as a highly selective, oral, allosteric BCR-ABL (BCR::ABL1) inhibitor. It is being developed for patients with chronic myeloid leukemia (CML), including those with previously treated or relapsed/refractory disease. Company materials characterize TERN-701 as an investigational therapy that could meaningfully improve upon the efficacy, safety and convenience of existing CML treatments.

Core focus and clinical development

Terns states that it has completed a transition to an oncology-focused company anchored by TERN-701 for CML. The drug is being evaluated in the CARDINAL trial (NCT06163430), a global, multicenter Phase 1/2 clinical study. According to company disclosures and related SEC filings, CARDINAL includes a dose escalation phase and a dose expansion phase designed to assess safety, tolerability and efficacy in patients with previously treated chronic phase CML.

The dose escalation portion of CARDINAL was completed with no dose-limiting toxicities observed up to a maximum dose of 500 mg once daily. Terns reports that the dose expansion portion randomizes patients to two dose cohorts, 320 mg or 500 mg once daily, with up to 40 patients per arm. Across company press releases and the related Form 8-K, Terns highlights data such as major molecular response (MMR) rates by 24 weeks, deep molecular response (DMR) rates, and safety findings, particularly in heavily pretreated and difficult-to-treat CML populations.

Therapeutic area and scientific approach

In its public communications, Terns consistently describes itself as a clinical-stage oncology company. The company’s stated goal is to deliver high impact medicines by reimagining known biological mechanisms. For TERN-701, this centers on allosteric inhibition of BCR-ABL in CML. Company materials emphasize oral administration, selectivity, and the potential to address patients who have received multiple prior tyrosine kinase inhibitors (TKIs), including asciminib, ponatinib and other marketed or investigational TKIs.

The CARDINAL trial data summarized in company news and SEC filings describe patient populations with multiple prior TKIs, baseline BCR::ABL1 transcript levels above 1% or 10%, and the presence of BCR::ABL1 mutations. Terns highlights overall and subgroup MMR rates, the maintenance of MMR, and the proportion of low-grade treatment-emergent adverse events, as part of its characterization of TERN-701’s clinical profile.

Pipeline and legacy programs

In addition to TERN-701, Terns has disclosed other programs and assets. The company refers to discovery efforts on undisclosed targets for oncology indications, indicating ongoing early-stage research in cancer beyond CML. Terns also references legacy metabolic programs and states that it is seeking strategic partners to advance them.

These legacy programs include TERN-501, described as an oral thyroid hormone receptor-beta (THR-β) agonist, and TERN-801, described as an oral small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist that was nominated as a development candidate from the TERN-800 series discovery effort. The company notes that it decided to discontinue internal clinical development of its metabolic programs and is looking to external partnerships to realize their potential.

Another disclosed program is TERN-601, an oral, small-molecule glucagon-like peptide-1 receptor agonist (GLP1-RA) that was evaluated in a Phase 2 study for obesity. Terns reports that top-line 12-week data showed a certain level of placebo-adjusted weight loss and treatment discontinuation due to adverse events, including asymptomatic, reversible grade 3 liver enzyme elevations in some participants. The company states that these results did not support further internal development of TERN-601 in obesity and reiterates its decision to no longer invest in metabolic disease internally.

Capital markets activity and financial reporting

Terns Pharmaceuticals is an SEC-reporting company and files periodic and current reports, including Form 8-K filings that reference quarterly financial results and clinical updates. The company has conducted underwritten public offerings of common stock, with press releases and related registration statements on Form S-3 describing offerings of shares of common stock and, in some cases, pre-funded warrants. These offerings are described as intended to fund research, clinical trials, development and manufacturing of key product candidates, including TERN-701, as well as initial activities related to potential future commercial launch of TERN-701, working capital and general corporate purposes.

In its financial communications, Terns reports operating expenses such as research and development and general and administrative costs, as well as cash, cash equivalents and marketable securities. The company also provides guidance on expected cash runway based on its operating plan. These details appear in press releases that are furnished or incorporated by reference in Form 8-K filings.

Regulatory and clinical milestones

Company news indicates that TERN-701 received U.S. FDA Fast Track designation for the treatment of CML. Terns also outlines anticipated milestones for TERN-701, including dose selection for pivotal studies, regulatory interactions such as an end-of-Phase 2 meeting with the U.S. Food and Drug Administration, updates to CARDINAL trial data, and plans for initiating pivotal trials in certain CML treatment lines. These milestones are described in company press releases as expectations and goals and are accompanied by cautionary notes regarding forward-looking statements.

Terns frequently highlights scientific and clinical presentations related to TERN-701, including oral presentations at major hematology conferences such as the American Society of Hematology (ASH) Annual Meeting. The company’s disclosures summarize efficacy and safety data from the CARDINAL trial, including MMR and DMR rates, safety profiles, and outcomes in subgroups with prior exposure to other TKIs.

Position within the biopharmaceutical landscape

According to company descriptions and SEC filings, Terns Pharmaceuticals operates as a clinical-stage biopharmaceutical organization with a primary focus on oncology, particularly CML. Its activities center on the clinical development of TERN-701, the management of legacy metabolic assets for potential partnering, and ongoing discovery work on additional oncology targets. Public statements emphasize the potential for TERN-701 to address unmet needs in CML, especially in patients who have received multiple prior therapies.

Investors and observers can follow Terns’ progress through its Nasdaq listing under the symbol TERN, its periodic SEC filings, and its press releases detailing clinical data, financial results, capital raises and corporate updates.

FAQs about Terns Pharmaceuticals, Inc. (TERN)

• What does Terns Pharmaceuticals, Inc. do?
  Terns Pharmaceuticals is a clinical-stage oncology company. It describes its mission as reimagining known biology to deliver high impact medicines, with a primary focus on developing drug candidates for cancer indications.
• What is TERN-701?
  TERN-701 is the company’s lead program, described as a highly selective, oral, allosteric BCR-ABL (BCR::ABL1) inhibitor. It is being developed as an investigational treatment for patients with chronic myeloid leukemia (CML), including previously treated and relapsed/refractory populations.
• What is the CARDINAL trial?
  The CARDINAL trial (NCT06163430) is a global, multicenter Phase 1/2 clinical study of TERN-701 in patients with previously treated chronic phase CML. It includes dose escalation and dose expansion components to evaluate safety, tolerability and efficacy at different once-daily doses.
• How does Terns describe its focus in oncology?
  Terns states that it has transitioned to an oncology company anchored by TERN-701 for CML. The company emphasizes developing high impact medicines in cancer by targeting known biological pathways with small-molecule drug candidates.
• What other programs has Terns disclosed?
  Beyond TERN-701, Terns has disclosed legacy metabolic programs such as TERN-501, an oral THR-β agonist, and TERN-801, an oral GIPR antagonist. It also reports discovery efforts on undisclosed targets for oncology indications and previously evaluated TERN-601, an oral GLP1 receptor agonist, in a Phase 2 obesity study.
• What is the status of Terns’ metabolic disease programs?
  Terns has stated that it decided to discontinue internal clinical development of its metabolic programs and to no longer invest internally in metabolic disease. The company is seeking strategic partners to advance programs such as TERN-501 and TERN-801.
• On which exchange does Terns trade and under what symbol?
  According to SEC filings, Terns Pharmaceuticals’ common stock is registered on the Nasdaq Global Select Market under the trading symbol TERN.
• How does Terns fund its clinical development?
  Terns has conducted underwritten public offerings of its common stock, as described in press releases and Form S-3 registration statements. The company states that it intends to use offering proceeds to fund research, clinical trials, development and manufacturing of key product candidates, including TERN-701, and for working capital and general corporate purposes.
• What regulatory designations has TERN-701 received?
  Company news reports that TERN-701 has been granted U.S. FDA Fast Track designation for the treatment of CML, reflecting regulatory recognition of the program’s potential in this indication.
• Where can investors find official information about Terns?
  Investors can review Terns Pharmaceuticals’ SEC filings, including Forms 8-K that reference financial results and clinical updates, as well as company press releases that summarize clinical data, capital markets activity and corporate developments.